Objective: To evaluate the clinical efficacy and adverse events of saccharomyces boulardii powder in treatment of infantile rotavirus enteritis. Methods: Selected 128 children with rotavirus enteritis in our hospital from November 2011 to November 2015, randomly divided into control group and experimental group, each of 64 cases. The children in the control group was administered conventional symptomatic treatment and oral montmorillonite powder, the experimental group were treated with saccharomyces boulardii powder as adjuvant therapy based on the control measures. The clinical efficacy and adverse reactions of the two groups were observed. Results: The total efficiency (98.4%) was significantly higher than that (81.2%) in the experimental group (χ2=10.36, P=0.00). The time of hospitalization, diarrhea, abdominal pain and the adverse reaction rate in the observation group was lower than those in the control group, the difference was statistically significant (P<0.01), the stool frequency of experimental group in 3 and 5 days after treatment was significantly lower than that of the control group (P<0.01). Infants of the two groups had no adverse reactions after treatment, the difference was not statistically significant (P>0.05). Conclusion: The effect of saccharomyces boulardii powder in infants and young children suffering from rotavirus enteritis is obvious. With rapid onset and rapid repair for intestinal cells, the saccharomyces boulardii powder hinders the development of rotavirus with high security features, and should be introduced in clinical practice.